{"id":386623,"date":"2020-11-23T08:03:32","date_gmt":"2020-11-23T13:03:32","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=386623"},"modified":"2020-11-23T08:03:32","modified_gmt":"2020-11-23T13:03:32","slug":"cabaletta-bio-to-participate-in-upcoming-december-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\/","title":{"rendered":"Cabaletta Bio to Participate in Upcoming December Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">PHILADELPHIA, Nov.  23, 2020  (GLOBE NEWSWIRE) &#8212; Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in December:<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Piper Sandler <\/strong><br \/>\n          <strong>32<\/strong><br \/>\n          <sup><br \/>\n            <strong>nd<\/strong><br \/>\n          <\/sup><br \/>\n          <strong> Annual <\/strong><br \/>\n          <strong>Virtual Healthcare Conference<\/strong><br \/>\n          <strong> on Wednesday, December 2, 2020<\/strong><br \/>\n          <strong>:<\/strong> A pre-recorded fireside chat with Dr. Nichtberger is now available on the company\u2019s website.<\/li>\n<li>\n          <strong>Evercore ISI <\/strong><br \/>\n          <strong>3<\/strong><br \/>\n          <sup><br \/>\n            <strong>rd<\/strong><br \/>\n          <\/sup><br \/>\n          <strong> Annual <\/strong><br \/>\n          <strong>Virtual <\/strong><br \/>\n          <strong>HealthCONx<\/strong><br \/>\n          <strong> Conference<\/strong><br \/>\n          <strong> on Thursday, December 3, 2020<\/strong><br \/>\n          <strong>: <\/strong>Live fireside chat with Dr. Nichtberger at 9:15 a.m. ET.<\/li>\n<\/ul>\n<p>All webcasts of presentations are available on the News and Events section of the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=T8RQaKeWHqbmwvgFZmxSZUmrVLoJ6M7Pq0pyABopgJfDRpb_6kSRDdFiJlLXrSb-3_dOteJjRVoIFc_DCqw6sWS6D9GV177-qJTvoHuLCu0=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.cabalettabio.com<\/a>. Following the presentations, a replay of the webcasts will be available on the website for 90 days.<\/p>\n<p>\n        <strong>About Cabaletta Bio<\/strong><br \/>\n        <br \/>Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabaletta\u2019s proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company\u2019s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes<sup>TM<\/sup> phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the clinical trial, please see <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0J8-5h-zDul5Hi1N5HGNC_MpanPoYzWGGMmJL9GydEckrTmRDnsdo0fHCTWjUvOmCKGHETHQQnCFy_adTCFbdP4q00W9rOm-qlm_dFEqm_hieZy66-IjU-fVi0IF20_y6dM4oYtI964DCaGQZrBG4rSDuOss8tlH20utdeXR8MJhGHdaPPPU74BlwcCRmlK0\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.clinicaltrials.gov<\/a>. The Company\u2019s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=T8RQaKeWHqbmwvgFZmxSZSXRzfJWIJkUVbYxnKq3qNyVIMUeRc-MKL-ZPWaXQuQubzjVUphDgJSb6s3dYZUjGWXtm66kGHunH6LtoLfwbjI=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.cabalettabio.com<\/a>.<\/p>\n<p>\n        <strong>Contacts:<\/strong><br \/>\n        <br \/>Anup Marda<br \/>Chief Financial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UophG_nUeVZUh_T3ZbojJ4qp6HBf811NQ0acvu9unrcE_iJ9qmTgAbBjHqhBVB-905KX84XAmzFCkcyuE8RtTo5m0XdKt7fqDzxmkVkg6j1WUJ_ga2-EnWtVmwXeTS1-\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>investors@cabalettabio.com<\/u><\/a><\/p>\n<p>Sarah McCabe<br \/>Stern Investor Relations, Inc.<br \/>212-362-1200<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=e8Dz0IEbw4ffkRQtSpL6cfAni1o1ln-nTEFEWLvejrGWQFCPgJJOnko6B7J9EEUwJ6dwBQErRVg4kQoGygf6uLcYPT00oCHNFdnxLma6GIQ=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">sarah.mccabe@sternir.com<\/a><\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDI1NyMzODM2NzI1IzIxMjUwMzA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/b26472c3-2fe9-43ab-97b0-ce81540fe17f\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PHILADELPHIA, Nov. 23, 2020 (GLOBE NEWSWIRE) &#8212; Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in December: Piper Sandler 32 nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020 : A pre-recorded fireside chat with Dr. Nichtberger is now available on the company\u2019s website. Evercore ISI 3 rd Annual Virtual HealthCONx Conference on Thursday, December 3, 2020 : Live fireside chat with Dr. Nichtberger at 9:15 a.m. ET. All webcasts of presentations are available on the News and Events section of the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cabaletta Bio to Participate in Upcoming December Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-386623","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cabaletta Bio to Participate in Upcoming December Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cabaletta Bio to Participate in Upcoming December Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA, Nov. 23, 2020 (GLOBE NEWSWIRE) &#8212; Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in December: Piper Sandler 32 nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020 : A pre-recorded fireside chat with Dr. Nichtberger is now available on the company\u2019s website. Evercore ISI 3 rd Annual Virtual HealthCONx Conference on Thursday, December 3, 2020 : Live fireside chat with Dr. Nichtberger at 9:15 a.m. ET. All webcasts of presentations are available on the News and Events section of the &hellip; Continue reading &quot;Cabaletta Bio to Participate in Upcoming December Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-23T13:03:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDI1NyMzODM2NzI1IzIxMjUwMzA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cabaletta Bio to Participate in Upcoming December Investor Conferences\",\"datePublished\":\"2020-11-23T13:03:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\\\/\"},\"wordCount\":341,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDI1NyMzODM2NzI1IzIxMjUwMzA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\\\/\",\"name\":\"Cabaletta Bio to Participate in Upcoming December Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDI1NyMzODM2NzI1IzIxMjUwMzA=\",\"datePublished\":\"2020-11-23T13:03:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDI1NyMzODM2NzI1IzIxMjUwMzA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDI1NyMzODM2NzI1IzIxMjUwMzA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cabaletta Bio to Participate in Upcoming December Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cabaletta Bio to Participate in Upcoming December Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Cabaletta Bio to Participate in Upcoming December Investor Conferences - Market Newsdesk","og_description":"PHILADELPHIA, Nov. 23, 2020 (GLOBE NEWSWIRE) &#8212; Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in December: Piper Sandler 32 nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020 : A pre-recorded fireside chat with Dr. Nichtberger is now available on the company\u2019s website. Evercore ISI 3 rd Annual Virtual HealthCONx Conference on Thursday, December 3, 2020 : Live fireside chat with Dr. Nichtberger at 9:15 a.m. ET. All webcasts of presentations are available on the News and Events section of the &hellip; Continue reading \"Cabaletta Bio to Participate in Upcoming December Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-23T13:03:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDI1NyMzODM2NzI1IzIxMjUwMzA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cabaletta Bio to Participate in Upcoming December Investor Conferences","datePublished":"2020-11-23T13:03:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\/"},"wordCount":341,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDI1NyMzODM2NzI1IzIxMjUwMzA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\/","name":"Cabaletta Bio to Participate in Upcoming December Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDI1NyMzODM2NzI1IzIxMjUwMzA=","datePublished":"2020-11-23T13:03:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDI1NyMzODM2NzI1IzIxMjUwMzA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDI1NyMzODM2NzI1IzIxMjUwMzA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cabaletta Bio to Participate in Upcoming December Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/386623","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=386623"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/386623\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=386623"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=386623"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=386623"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}